A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT02412371. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer (NSCLC)
Study identification
- NCT ID
- NCT02412371
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Interventions
- Paclitaxel Drug
- Placebo for Veliparib Drug
- Carboplatin Drug
- Veliparib Drug
- Radiotherapy Radiation
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 29, 2015
- Primary completion
- Aug 4, 2019
- Completion
- Aug 4, 2019
- Last update posted
- Jul 21, 2020
2015 – 2019
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ucsd /Id# 133037 | La Jolla | California | 92093 | — |
| Christiana Care Health Service /ID# 133486 | Newark | Delaware | 19713 | — |
| University of Chicago /ID# 133828 | Chicago | Illinois | 60637-1443 | — |
| Univ Maryland School Medicine /ID# 132944 | Baltimore | Maryland | 21201 | — |
| Dana-Farber Cancer Institute /ID# 133494 | Boston | Massachusetts | 02215 | — |
| SUNY Upstate Medical University - Downtown /ID# 133492 | Syracuse | New York | 13210 | — |
| Unc /Id# 133496 | Chapel Hill | North Carolina | 27599 | — |
| Duke University Medical Center /ID# 133497 | Durham | North Carolina | 27710-3000 | — |
| Wake Forest Univ HS /ID# 134608 | Winston-Salem | North Carolina | 27157 | — |
| Rhode Island Hospital /ID# 133493 | Providence | Rhode Island | 02903 | — |
| The Miriam Hospital /ID# 133910 | Providence | Rhode Island | 02906 | — |
| University of Virginia /ID# 133495 | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02412371, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2020 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02412371 live on ClinicalTrials.gov.